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Abstr Act
AnJiopoietinliNe protein  AN*37Lbetatrophin e[pression in vis
Feral aGipose tissXe anG assoFiations Zith FirFXlatinJ Iatt\ aFiG proÀle 
have not \et been investiJateG.
Fort\ sXbMeFts Zere inFlXGeG in a FrossseFtional stXG\ 7 in a Gietar\ 
ZeiJht reGXFtion intervention. CirFXlatinJ AnJiopoietinliNe protein 
betatrophin Zas measXreG in all sXbMeFts. Liver anG aGipose tissXe Zere 
sampleG anG plasma Iatt\ aFiGs anG tissXe AnJiopoietinliNe protein 
betatrophin e[pression Zere evalXateG in the FrossseFtional stXG\. ,n 
the intervention stXG\ oral JlXFose testinJ anG liver maJnetiF resonanFe 
sFanninJ at baseline anG aIter  months Zere perIormeG. AnJiopoie
tinliNe protein betatrophin mRNA Zas inFreaseG in visFeral FompareG 
to sXbFXtaneoXs aGipose tissXe p  0.001. CirFXlatinJ AN*37Lbeta
trophin ForrelateG Zith liver steatosis r  0.42 p  0.047 triaF\lJl\Ferols 
r  0.34 p  0.04 satXrateG r  0.43 p  0.022 monoXnsatXrateG 
r  0.1 p  0.007 anG pol\XnsatXrateG Iatt\ aFiGs r   ï 0.3 p  0.004. 
,n the intervention stXG\ baseline AnJiopoietinliNe protein betatro
phin ForrelateG Zith aJe r  0.32 p  0.010 anG triaF\lJl\Ferols r  0.30 
p  0.02 anG Zas inFreaseG Zith hepatiF steatosis p  0.033. :eiJht loss 
reGXFeG liver Iat b\ 4  anG FirFXlatinJ AnJiopoietinliNe protein be
tatrophin b\ 11  2  17 vs. 2  17 pJml; p  0.01. AnJiopoie
tinliNe protein betatrophin is relateG to liver steatosis Zhile visFeral 
aGipose tissXe represents an aGGitional site oI e[pression in hXmans.
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Abbreviations
A8C  Area XnGer the FXrve
AT  Adipose tissue
BM,  BoG\ mass inGe[
(L,6A  (nz\melinNeG immXnosorbent assa\
FA  Fatt\ aFiGs
FAM(  Fatt\ aFiG meth\l esters
H2MA,R  Homeostasis moGelassessment oI insXlin resistanFe
mRNA  MessenJer ribonXFleiF aFiG
NAFLD  NonalFoholiF Iatt\ liver Gisease
SCAT  Subcutaneous adipose tissue
72D  7\pe 2 Giabetes mellitXs
9A7  9isFeral aGipose tissXe
,ntroGXFtion
,n a reFent animal stXG\ AnJiopoietinliNe protein  AN*37L 
also NnoZn as betatrophin hXman C192RF0 lipasin or R,FL Zas 
reporteG to promote panFreatiF betaFell mass proliIeration in ro
Gents Zhile amelioratinJ JlXFose metabolism >1 2@. HoZever this 
ÀnGinJ FoXlG not be reproGXFeG b\ others >3@. ,n hXmans most 
>4–@ bXt not all >9 10@ FliniFal stXGies in t\pe 2 Giabetes mellitXs 
72D observeG Forrelations oI FirFXlatinJ AN*37Lbetatrophin 
Zith variables oI JlXFose homeostasis. Moreover even GiabetiF ne
phropath\ anG retinopath\ have been relateG to a Fomple[ netZorN 
oI involveG biomarNers inFlXGinJ FirFXlatinJ AN*37Lbetatrophin 
>11–13@. 2therZise no relationship oI AN*37Lbetatrophin Zith 
CpeptiGe levels FoXlG be establisheG in GiabetiF patients >14 1@. 
7he latter is sXpporteG b\ e[perimental Gata inGiFatinJ that asso
Fiations oI AN*37Lbetatrophin anG JlXFose metabolism Fannot 
larJel\ be e[plaineG b\ enhanFeG insXlin seFretion >1 17@. 7here
Iore effeFts on insXlin sensitive tissXes ma\ FontribXte to the ob
serveG relationship.
NonalFoholiF Iatt\ liver Gisease NAFLD preGisposes hXmans 
to 72D >1@ as NAFLD is Flosel\ relateG to insXlin resistanFe resXlt
inJ in h\perinsXlinemia h\perJl\Femia anG h\pertriaF\lJl\Fer
olemia >19 20@. 7he liver Zas reporteG as a maMor site oI AN*37L
betatrophin e[pression in hXmans >21@. Moreover AN*37Lbe
tatrophin is assoFiateG Zith G\slipiGemia in roGents anG hXmans 
>3  9@ partiFXlarl\ beinJ involveG in triaF\lJl\Ferol metabolism 
>22@. AFForGinJl\ Ze h\pothesizeG that liver Iat anG AN*37Lbe
tatrophin proGXFtion FoXlG interaFt loFall\ anG thereb\ shoZ in
terrelations Zith insXlin resistanFe anG FirFXlatinJ lipiG proÀles. 
7hereIore in a FrossseFtional Fohort anG an inGepenGent inter
vention stXG\ Ze testeG the h\pothesis that hepatiF steatosis is 
relateG to AN*37Lbetatrophin in hXmans anG that liver Iat re
GXFtion GXe to h\poFaloriF GietinJ reGXFes FirFXlatinJ AN*37L
betatrophin. :e moreover evalXateG Zhether blooG lipiGs anG 
main Iatt\ aFiG FA speFies in plasma are assoFiateG Zith AN*37L
betatrophin. As aGipose tissXe A7 represents an alternative site 
oI AN*37Lbetatrophin mRNA e[pression >21@ Ze Ànall\ Geter
mineG Zhether in hXmans visFeral aGipose tissXe 9A7 anG sXb
FXtaneoXs aGipose tissXe 6CA7 shoZ Fomparable e[pression lev
els oI AN*37Lbetatrophin anG hoZ these relate to FirFXlatinJ 
levels.
6XbMeFts anG MethoGs
Study groups and ethics
:e investiJateG sXbJroXps Irom 2 inGepenGent stXGies. 7he stXG\ 
protoFol Zas approveG b\ the institXtion·s hXman researFh Fom
mittee respeFtivel\. ,nIormeG Fonsent Zas obtaineG Irom all pa
tients Ior beinJ inFlXGeG in the stXG\. ,nIormeG Fonsent Zas ob
taineG aIter IXll e[planation oI the pXrpose anG natXre oI all pro
FeGXres XseG. All proFeGXres IolloZeG Zere in aFForGanFe Zith the 
ethiFal stanGarGs oI the responsible Fommittee on hXman e[peri
mentation institXtional anG national anG Zith the HelsinNi DeF
laration oI 197 as reviseG in 200.
:e inFlXGeG sXbMeFts Irom the FrossseFtional ,N6,*H7 *er
man CliniFal 7rialsReJister: DR.6000040 stXG\ >23@. 7his JroXp 
FompriseG 24 partiFipants FharaFterizeG b\ the presenFe oI histo
loJiFall\ proven liver steatosis bXt absenFe oI 72D anG 1 sXbMeFts 
ZithoXt hepatiF steatosis insXlin resistanFe or 72D. :e IXrther 
anal\zeG 7 partiFipants oI the B6MAR7 CliniFal7rials.Jov ,Gen
tiÀer: NC7009 stXG\. 7he B6MAR7 stXG\ Zas GesiJneG as a 
prospeFtive ranGomizeG trial to Fompare ZeiJht loss anG FhanJes 
oI metaboliF anG FarGiovasFXlar variables Zith reGXFeG Farboh\
Grate or reGXFeG Iat h\poFaloriF Giets >24@.
Basic characteristics, clinical chemistry and assays
MeGiFal histor\ anG anthropometr\ Zere evalXateG. 2ral JlXFose 
toleranFe testinJ Zas perIormeG in B6MAR7 sXbMeFts >24@. ,nsXlin 
resistanFe Zas estimateG b\ the homeostasis moGelassessment 
oI insXlin resistanFe H2MA,R blooG JlXFose insXlin lipiGs anG 
inÁammator\ marNers Zere measXreG b\ stanGarG methoGs in all 
sXbMeFts in FertiÀeG CliniFal Chemistr\ Laboratories >23 24@. Cir
FXlatinJ AN*37Lbetatrophin Zas anal\zeG b\ enz\melinNeG im
mXnosorbent assa\ (L,6A; :Xhan (iaab 6FienFe :Xhan China; 
(1144h intraassa\ Foe͆Fient oI variation   4.  interassa\ Fo
e͆Fient oI variation   7.2 . CirFXlatinJ aGiponeFtin AL3C2 ,m
mXnoassa\s 6alem NH 86A; 47AD3H8(01 Zas measXreG in 
B6MAR7 partiFipants.
Sampling of tissue specimen
,n ,N6,*H7 sXbMeFts liver speFimen Zere harvesteG Irom a health\ 
liver seJment anG histopatholoJ\ Zas evalXateG aFForGinJ to aFFept
eG Friteria >23@. Liver sXrJer\ Zas inGiFateG Ior nonmaliJnant or ma
liJnant inGiFation. 6amples oI 6CA7 anG 9A7 Zere taNen b\ NniIe e[
traFtion in the same sXrJiFal settinJ. All samples Zere immeGiatel\ 
Áash Irozen in liTXiG nitroJen anG storeG at  ï 0 C Xntil anal\sis.
Lipid analysis
LipiGs Zere e[traFteG Irom plasma oI ,N6,*H7 sXbMeFts n  27 anG 
anal\zeG Ior FA speFies >2@. FA FonFentrations are e[presseG as 
the perFentaJe oI the total area oI all FA peaNs   oI total Iatt\ aFiG 
meth\l esters FAM(.
Oral glucose tolerance test
AIter an overniJht Iast blooG samples Zere obtaineG in B6MAR7 
sXbMeFts at baseline anG aIter oral JlXFose loaGinJ 7 J JlX
Fose00 ml at 1 30 4 0 7 90 anG 120 min Ior anal\sis oI 
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Magnetic resonance spectroscopy of the liver
All inFlXGeG B6MAR7 sXbMeFts haG FompleteG a maJnetiF reso
nanFe MR sFan at baseline n  7 anG aIter  months Gietar\ in
tervention n  2 >24@. ,ntrahepatiF lipiG ,HL Fontent Zas as
sesseG b\ 1H MR speFtrosFop\ oI the liver >24@.
Real time PCR
AN*37Lbetatrophin messenJer mRNA Zas anal\zeG in liver tis
sXe 6CA7 anG 9A7 oI ,N6,*H7 sXbMeFts b\ means oI realtime 3CR 
>2@. 3rimer seTXenFes XseG Ior anal\sis Zere as IolloZs: ʋC7
*7CCC*7A*CACC77C7*3ʋ anG ʋCA*AA**7*C7AC***A
CA*3ʋ Ior AN*37Lbetatrophin; ʋ7*ACAC7**CAAAACAA7*
CA3ʋ anG ʋ**7CC7777CACCA*CAA*C73ʋ Ior h\po[an
thineJXanine phosphoribos\ltransIerase 1 H3R71 ZhiFh Zas 
XseG Ior normalization.
Statistics
Data Zere anal\zeG Zith ,BM 6366 22.0 ChiFaJo ,L 86A. Data are 
Jiven as mean  6(M iI not otherZise stateG. LoJarithmiF transIor
mation oI Gata Zas perIormeG iI reTXireG. DepenGinJ on Gata Gis
tribXtion the IolloZinJ proFeGXres Zere XseG: 3earson·s or 6pear
man·s ranN Forrelation Foe͆Fient .rXsNal:allis test Zith BonIer
roni post hoF aGMXstment Ior mXltiple testinJ 6tXGent·s ttest or 
Mann–:hitne\ 8test. 6iJniÀFanFe level Zas GeÀneG as 2siGeG 
p  0.0.
ResXlts
ANGPTL8/betatrophin mRNA expression in INSIGHT 
subjects
:e GeteFteG AN*37Lbetatrophin mRNA in the liver oI 97  oI all 
,N6,*H7 sXbMeFts in 9A7 oI 92  anG in 6CA7 oI 7 . No assoFia
tion oI either 6CA7 r   ï 0.1 p  0.41 9A7 r   ï 0.27 p  0.13 
or liver r   ï 0.13 p  0.47 AN*37Lbetatrophin mRNA Zith Fir
FXlatinJ levels Zas IoXnG. 2therZise aIter aGMXstment Ior aJe Fir
FXlatinJ AN*37Lbetatrophin ForrelateG Zith 9A7 mRNA 
r   ï 0.33 p  0.0 anG siJniÀFantl\ Zith FombineG mRNA levels 
oI liver tissXe 9A7 anG 6CA7 r   ï 0.3 p  0.029. Moreover liver 
mRNA Zas relateG to FirFXlatinJ AN*37Lbetatrophin aIter aG
MXstment Ior H2MA,R r   ï 0.3 p  0.034. RemarNabl\ in A7 Ze 
observeG siJniÀFantl\ hiJher AN*37Lbetatrophin mRNA levels 
in 9A7 as FompareG to 6CA7 p  0.001; ̓ Fig. 1 Zhere e[pression 
levels Zere neJliJible.
Associations of ANGPTL8/betatrophin with NAFLD 
related variables in INSIGHT
CharaFteristiFs oI the ,N6,*H7 JroXp are Jiven in ̓ table 1. Circu
latinJ AN*37Lbetatrophin Zas nXmeriFall\ inFreaseG in NAFLD 
vs. nonNAFLD sXbMeFts bXt this GiG not reaFh statistiFal siJniÀ
FanFe p  0.0; ̓ table 1. CirFXlatinJ levels Zere positivel\ Forre
lateG Zith hepatiF steatosis r  0.42 p  0.047; ̓ Fig. 2 aJe 
r  0.44 p  0.00 serXm triaF\lJl\Ferols r  0.34 p  0.04 
plasma satXrateG FA r  0.43 p  0.022; suppl. Fig. 1s anG plas
ma monoXnsatXrateG FA r  0.1 p  0.007; suppl. Fig. 2s. B\ 
Fontrast a neJative assoFiation oI FirFXlatinJ AN*37Lbetatro
phin anG plasma pol\XnsatXrateG FA Zas observeG r   ï 0.3 
p  0.004; suppl. Fig. 3s. AIter aGMXstment Ior aJe FirFXlatinJ 
AN*37Lbetatrophin Zas neJativel\ relateG to loZ Gensit\ lipo
protein LDL r   ï 0.3 p  0.042 anG hiJh Gensit\ lipoprotein 
HDL r   ï 0.37 p  0.029.
HepatiF AN*37Lbetatrophin mRNA ForrelateG Zith the NA6 
r  0.3 p  0.023 hepatiF steatosis r  0.2 p  0.009; suppl. 
Fig. 4s hepatoF\te ballooninJ GeJeneration r  0.4 p  0.003 
anG H2MA,R r  0.3 p  0.030. 2therZise no assoFiations Zere 
IoXnG reJarGinJ IXrther variables oI JlXFose metabolism.
Modification of ANGPTL8/betatrophin by long term 
dietary intervention in B-SMART subjects
Baseline FharaFteristiFs oI B6MAR7 partiFipants are Jiven in 
̓table 2. Baseline anal\sis oI FirFXlatinJ AN*37Lbetatrophin in 
the B6MAR7 Fohort revealeG a Forrelation Zith aJe r  0.32 
p  0.010 anG serXm triaF\lJl\Ferols r  0.30 p  0.020; suppl. 
Fig. 5s. A Flose to siJniÀFant Forrelation Zas also observeG Zith 
area XnGer the FXrve A8C insXlin GXrinJ the oral JlXFose toler
anFe test r  0.2 p  0.02; suppl. Fig. 6s. :ith aGMXstment Ior 
aJe the Forrelation Zith insXlin A8C beFame siJniÀFant r  0.33 
p  0.012 Zhile the Forrelation Zith serXm triaF\lJl\Ferols re
maineG XnFhanJeG r  0.32 p  0.02. :hen stratiÀeG aFForGinJ 
to ,HL Fontent partiFipants Zith hepatiF steatosis haG elevateG 
AN*37Lbetatrophin FompareG to partiFipants Zith normal liver 
Iat Fontent p  0.033; ̓Fig. 3. :ith GietinJ boG\ ZeiJht Ge
FreaseG .9 NJ  ï 7.4  toJether Zith reGXFtions in ,HL b\ 4  anG 
plasma AN*37Lbetatrophin b\ 11  2  17 vs. 2  17 pJml; 
p  0.01; ̓Fig. 4. CirFXlatinJ AN*37Lbetatrophin reGXFtions 
tenGeG to be more pronoXnFeG on the reGXFeG Iat FompareG Zith 
the reGXFeG Farboh\Grate Giet  ï 37  17 vs.  ï 20  17 pJml.
̓Fig. 1 AN*37Lbetatrophin mRNA in sXbFXtaneoXs vs. visFeral 
aGipose tissXe. AN*37Lbetatrophin mRNA Zas GeteFtable in 92  
oI 9A7 samples in ,N6,*H7 stXG\ sXbMeFts anG 7  6CA7 samples. 
Levels oI AN*37Lbetatrophin mRNA Zere siJniÀFantl\ inFreaseG in 
hXman 9A7 FompareG to 6CA7 p  0.001. 6CA7: 6XbFXtaneoXs 
aGipose tissXe; 9A7: 9isFeral aGipose tissXe. Bo[es span Irom 2th–
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Discussion
2Xr stXG\ inGiFates that AN*37Lbetatrophin mRNA is e[presseG 
at hiJher levels in hXman visFeral FompareG to sXbFXtaneoXs aGi
pose tissXe anG Ze e[panG previoXs ÀnGinJs b\ shoZinJ Forrela
tions oI AN*37Lbetatrophin Zith main Iatt\ aFiG speFies in 
hXman plasma. :e IXrther FonÀrm reJXlation oI AN*37Lbeta
trophin b\ nXtritional interventions anG assoFiations Zith liver ste
atosis aJe parameters oI insXlin resistanFe anG lipiG metabolism 
in 2 inGepenGent FolleFtives.
A Fentral \et not IXll\ elXFiGateG aspeFt is the tissXe speFiÀF 
FontribXtion to FirFXlatinJ AN*37Lbetatrophin levels. 7he mRNA 
e[pression oI AN*37Lbetatrophin Zas reporteG to be ver\ hiJh 
in the liver FompareG to other orJans anG tissXes in hXmans Zhile 
in miFe A7 Zas iGentiÀeG as an aGGitional e[pression site >1 21@. ,n 
oXr stXG\ hepatiF AN*37Lbetatrophin mRNA ForrelateG Zith 
FirFXlatinJ levels aIter aGMXstment Ior H2MA,R sXpportinJ the 
liver as a main FontribXtor. HoZever FontrastinJ Zith earlier ÀnG
inJs >1 21@ AN*37Lbetatrophin mRNA Zas also abXnGantl\ e[
presseG in 9A7 in oXr sXbMeFts. 7his observation Zas sXpporteG b\ 
a Forrelation oI 9A7 mRNA Zith aJe aGMXsteG FirFXlatinJ AN*37L
betatrophin. 2therZise hXman e[pression patterns in Iat tissXes 
Zere previoXsl\ anal\zeG in FommerFiall\ available FDNA arra\s 
anG FharaFteristiFs oI the Gonor popXlation remain thereIore Xn
reporteG >21@. 2Xr speFimen Zere harvesteG intraoperativel\ XnGer 
perIXseG FonGitions Irom FharaFterizeG patients. 9ariable resXlts 
FoXlG thereIore be at least partiall\ attribXteG to potential Giffer
enFes reJarGinJ the Gonor JroXps. :e moreover observeG 
AN*37Lbetatrophin mRNA e[pression in 9A7 to be hiJher Fom
̓table 1 CharaFteristiFs oI ,N6,*H7 partiFipants >23@.
characteristics Non NAFLD NAFLD p-Value
n   male 1 31 24 4 –
AJe \ears 4  4 0  3 0.24
BoG\ mass inGe[ NJmò 23.  0.9 27.0  1.4 0.075
:aist FirFXmIerenFe Fm 7.2  3.7 9.3  3.0 0.044
NAFLD aFtivit\ sFore 0– 0.2  0.1 2.2  0.2   0.001
BallooninJ GeJeneration 0–2 0 0.3  0.1 0.28
Liver inÁammation 0–3 0.2  0.1 0.7  0.2 0.075
Fibrosis 0–4 1.1  0.3 1.1  0.3 0.90
Liver steatosis   0.4  0.3 20.  4.0   0.001
Alaninetransaminase 8l 41  1 47   0.16
CreaFtive protein mJGl 1.2  0. 2.3  0. 0.13
7riaF\lJl\Ferols mmoll 1.2  0.1 1.3  0.1 0.50
LDL Fholesterol mmol 3.3  0.3 3.2  0.2 0.90
HDL Fholesterol mmoll 1.3  0.1 1.2  0.1 0.77
BlooG JlXFose mmoll 4.9  0.2 .2  0.3 0.27
H2MA,R 1.  0. 2.  0. 0.12
HbA1F mmolmol 3.2  1.9 3.4  1.4 0.51
CirFXlatinJ AN*37Lbetatrophin pJml 1 01.  191.1 1 213.9  203. 0.80
Data are Jiven as means  6.(. or absolXte nXmbers respeFtivel\
HDL: HiJhGensit\ lipoprotein; H2MA,R: Homeostasis moGel oI insXlin resistanFe; LDL: LoZGensit\ lipoprotein; NAFLD: NonalFoholiF Iatt\ liver 
Gisease; NA6: NAFLD aFtivit\ sFore
̓Fig. 2 AssoFiation oI FirFXlatinJ AN*37Lbetatrophin Zith 
hepatiF steatosis in ,N6,*H7 sXbMeFts. 6Fatter plots illXstrate Forrela
tion oI FirFXlatinJ AN*37Lbetatrophin Zith loJarithmizeG liver 
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pareG to 6CA7 Zhile previoXs stXGies shoZinJ loZer AN*37Lbe
tatrophin mRNA e[pression in A7 GiG not separatel\ IoFXs on 9A7 
anG 6CA7 >1 21@. 7his IXrther FontribXtes to e[plain FontrastinJ 
resXlts. 6Xpport Ior oXr ÀnGinJs Fomes Irom a reFent stXG\ in hX
mans Zhere the aXthors also GeteFteG AN*37Lbetatrophin 
mRNA e[pression in hXman 6CA7 >27@. ,n aFForGanFe Zith the lat
ter anG earlier ÀnGinJs Irom others >1 21 27 2@ 6CA7 e[pression 
in oXr stXG\ Zas relativel\ loZ. Moreover h\pothesizinJ that pre
vioXs stXGies mainl\ investiJateG AN*37Lbetatrophin mRNA e[
pression in 6CA7 oXr Gata proviGe eviGenFe Ior the Àrst time that 
9A7 represents another FontribXtor to FirFXlatinJ AN*37Lbeta
trophin in hXmans. 7aNen toJether the liver anG A7 FoXlG variabl\ 
FonribXte to FirFXlatinJ AN*37Lbetatrophin in hXmans Zhere
b\ aJe nXtrition anG insXlin levels FoXlG represent main reJXlatinJ 
IaFtors >22 27@.
MXltiple lines oI eviGenFe linN AN*37Lbetatrophin to lipiG me
tabolism >22@. 3artiFXlarl\ an important role oI AN*37Lbetatro
phin in hepatiF ver\ loZ Gensit\ lipoproteins 9LDL proGXFtion has 
been proposeG >21 22@. ,n these stXGies AnJptlbetatrophin 
NnoFNoXt miFe shoZeG reGXFeG plasma triaF\lJl\Ferol levels aIter 
reIeeGinJ ZhiFh Zas e[plaineG b\ reGXFeG 9LDL seFretion in line 
Zith enhanFeG lipoprotein lipase aFtivit\ >29@. Conversel\ IorFeG 
AN*37Lbetatrophin e[pression proGXFeG h\pertriaF\lJl\Fer
olemia >3@. ,n sXpport oI these e[perimental Gata Ze observeG siJ
niÀFant assoFiations oI AN*37Lbetatrophin Zith FirFXlatinJ tri
aF\lJl\Ferols in 2 inGepenGent hXman FolleFtives. :e IXrther e[
panG previoXs ÀnGinJs b\ sXJJestinJ a FontrastinJ relationship 
Zith pol\XnsatXrateG vs. satXrateG anG monoXnsatXrateG FA in 
plasma. 7his FoXlG be oI interest sinFe AN*37Lbetatrophin is 
NnoZn to be nXtritionall\ reJXlateG >4 21 22@ Zhereb\ oXr inter
vention sXpports the impaFt oI Gietar\ manipXlation also in the 
lonJ term. :hether hoZever this effeFt is Ànall\ meGiateG b\ the 
observeG reGXFtion oI liver lipiGs a GeFreaseG intaNe in that is 6FA 
Zith a FonseFXtivel\ moGiÀeG FirFXlatinJ FA proÀle a Fombination 
oI these IaFtors or other \et XnNnoZn inÁXenFes Fannot be an
sZereG Zith oXr FXrrent stXG\ GesiJn. 2therZise oXr Gata evolve 
the h\pothesis that Gifferent FA speFies FoXlG have var\inJ impaFt 
on the reJXlation oI AN*37Lbetatrophin. ,nGeeG treatment Zith 
pol\XnsatXrateG FA represents an establisheG therapeXtiF ap
proaFh in reGXFinJ elevateG plasma triaF\lJl\Ferols >30@. A poten
tial role oI AN*37Lbetatrophin in that reJarG remains hoZever 
to be GeÀneG.
̓table 2 Baseline FharaFteristiFs oI B6MAR7 partiFipants >24@.
characteristics Low carb Low fat p-Val-
ue
n   male 27 7 30 20 –
AJe \ears 44  2 4  2 0.55
BoG\ mass inGe[ NJmò 33.0  1.0 33.1  0.7 0.93
:aist FirFXmIerenFe Fm 100  2 102  2 0.47
,HL   .  1.4 9.  1.7 0.16
Alanine aminotransami
nase 8l
21  2 30  4 0.06
CreaFtive protein mJGl 1.2  0.2 1.  0.3 0.32
7riaF\lJl\Ferols mmoll 1.2  0.1 1.2  0.1 0.92
LDL Fholesterol mmoll 2.9  0.1 3.2  0.1 0.14
HDL Fholesterol mmoll 1.3  0.1 1.3  0.1 0.82
BlooG JlXFose mmoll .  0.1 .4  0.1 0.75
H2MA,R 1.3  0.2 1.  0.2 0.11
CirFXlatinJ AN*37L
betatrophin pJml
279  23 297  2 0.62
Data are Jiven as means  6.(. or absolXte nXmbers respeFtivel\
HDL: HiJhGensit\ lipoprotein; H2MA,R: Homeostasis moGel oI 
insXlin resistanFe; ,HL: ,ntrahepatiF lipiGs; LDL: LoZGensit\ 
lipoprotein
̓Fig. 3 AssoFiations oI AN*37Lbetatrophin Zith hepatiF steato
sis in the B6MAR7 Fohort. 6tratiÀFation aFForGinJ to ,HL revealeG 
that sXbMeFts Zith hepatiF steatosis 20.1  2.  ,HL n  1 haG 
elevateG AN*37Lbetatrophin FompareG to nonsteatotiF 
4.0  0.4  ,HL n  42 sXbMeFts p  0.033. Data are shoZn as 
mean  6(M; ,HL intrahepatiF lipiGs;    p  0.0.
̓Fig. 4 AssoFiation oI AN*37Lbetatrophin Zith ZeiJht loss in 
B6MAR7. AIter a mean ZeiJht loss oI .9 NJ   7.4  initial boG\ 
ZeiJht GXe to Gietar\ intervention aFFompanieG b\ a 4  ,HL 
reGXFtion AN*37Lbetatrophin GeFreaseG b\ 11  p  0.01. Data 
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,nsXlin resistanFe is NnoZn to be relateG to NAFLD >31 32@. ,n oXr 
stXG\ FirFXlatinJ AN*37Lbetatrophin ForrelateG Zith insXlin A8C 
at least aIter aGMXstment Ior aJe. 7his Forrelation GisappeareG Iol
loZinJ 4  liver lipiG reGXFtion Zith FonFomitant AN*37Lbeta
trophin GeFrease. FXrthermore both FirFXlatinJ anG hepatiF 
AN*37Lbetatrophin ForrelateG siJniIiFantl\ Zith histoloJiFal 
proven liver steatosis. Moreover hepatiF mRNA e[pression Zas re
lateG to H2MA,R Zhile FirFXlatinJ levels ForrelateG Zith hepatiF 
mRNA e[pression aIter aGMXstment Ior H2MA,R. 7hereIore oXr 
ÀnGinJs sXJJest that hepatiF lipiG Fontent FoXlG pla\ a role to e[
plain the previoXsl\ observeG assoFiation oI AN*37Lbetatrophin 
Zith variables oI JlXFose metabolism >4–@. ,n sXpport oI the IaFt 
that liver Iat is aFFepteG as the most important preGiFtor oI hXman 
insXlin resistanFe >1@ siJniÀFantl\ elevateG FirFXlatinJ AN*37L
betatrophin Zas reFentl\ reporteG in NAFLD patients Zhile the ob
serveG assoFiation Zas abolisheG aIter statistiFal aGMXstment Ior in
sXlin resistanFe >33@. 7hereb\ it is oI maMor siJniÀFanFe that G\slipi
Gemia anG partiFXlarl\ h\pertriaF\lJl\Ferolemia are aFNnoZleGJeG 
IeatXres oI hepatiF insXlin resistanFe >20 31@. 7hereIore althoXJh 
Ze IoXnG a siJniÀFant assoFiation oI AN*37Lbetatrophin Zith he
patiF steatosis Ze h\pothesize that the laFN oI GifferenFe reJarGinJ 
FirFXlatinJ AN*37Lbetatrophin in in oXr NAFLD vs. nonNAFLD 
sXbMeFts Zas rather e[plaineG b\ minor GifferenFes betZeen JroXps 
in lipiG metabolism than b\ liver steatosis per se.
2Xr stXG\ is limiteG b\ laFN oI meFhanistiF eviGenFe anG Fannot 
prove FaXsalit\. Nevertheless oXr stXG\ shoZeG a robXst assoFia
tion betZeen AN*37Lbetatrophin anG hepatiF steatosis in 2 in
GepenGent Fohorts XsinJ in vivo anG e[ vivo JolG stanGarG meth
oGs Ior liver lipiG TXantiÀFation. :hile Ze investiJateG a limiteG 
nXmber oI hXman sXbMeFts assoFiations betZeen AN*37Lbeta
trophin anG NAFLD Zere eviGent in both Fohorts.
,n oXr stXG\ FirFXlatinJ AN*37Lbetatrophin Zas GetermineG 
XsinJ the NterminXs reFoJnizinJ (L,6A anG samples in both oI oXr 
stXGies Zere obtaineG anG storeG XnGer Fomparable stanGarG Fon
Gitions. 8sinJ the NterminXs reFoJnizinJ (L,6A Fenzl et al. >10@ 
vs. HX et al. >@ observeG aboXt 4IolG hiJher AN*37Lbetatro
phin levels in health\ Fontrols Zith Fomparable BM,. ,n oXr stXG\ 
liver AN*37Lbetatrophin mRNA ForrelateG Zith the (L,6A Geter
mineG levels proviGinJ eviGenFe Ior the valiGit\ oI the measXre
ments. HoZever FirFXlatinJ AN*37Lbetatrophin levels Zere 
aboXt 4IolG hiJher in ,N6,*H7 FompareG to B6MAR7 sXbMeFts. 
2therZise the GeteFteG GifferenFes are Flearl\ in line Zith previ
oXs repor ts shoZinJ Fomparable ranJes oI  var iabi l i t \ 
>4   10 33@. HoZever Zith oXr FXrrent stXG\ GesiJn Ze Fannot 
IXll\ e[plain the observeG GifferenFes.
2Xr Gata sXJJest the liver anG visFeral aGipose tissXe as Fontrib
Xtors to FirFXlatinJ AN*37Lbetatrophin in hXmans. HepatiF lipiG 
aFFXmXlation as FritiFal Geterminant oI G\slipiGemia anG insXlin 
resistanFe is relateG to hXman AN*37Lbetatrophin. FXtXre stXG
ies neeG to aFFoXnt Ior hepatiF lipiG Fontent anG FirFXlatinJ Iatt\ 
aFiG proÀle as variables to variation in AN*37Lbetatrophin.
study registration: CliniFal7rials.Jov ,GentiÀer: NC7009; 
*erman CliniFal 7rialsReJister: DR.6000040.
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